DarioHealth (DRIO) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 11, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Registrant Name	DarioHealth Corp.
Entity Central Index Key	1,533,998
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	DRIO
Entity Common Stock, Shares Outstanding		9,754,887

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 3,898	$ 1,093
Short-term bank deposits	243	225
Trade Receivables	372	226
Inventories	717	888
Other accounts receivable and prepaid expenses	632	504
Total current assets	5,862	2,936
LEASE DEPOSITS	42	35
PROPERTY AND EQUIPMENT, NET	831	901
Total assets	6,735	3,872
CURRENT LIABILITIES:
Trade payables	985	1,812
Other accounts payable and accrued expenses	1,794	1,113
Total current liabilities	2,779	2,925
LIABILITY RELATED TO WARRANTS	3	7,488
STOCKHOLDERS' EQUITY (DEFICIENCY)
Common Stock of $0.0001 par value - Authorized: 160,000,000 shares at June 30, 2017 (unaudited) and December 31, 2016; Issued and Outstanding: 9,599,234 and 5,713,383 shares at June 30, 2017 (unaudited) and December 31, 2016, respectively	6	6
Preferred Stock of $0.0001 par value - Authorized: 5,000,000 shares at June 30, 2017 (unaudited) and December 31, 2016; Issued and Outstanding: None at June 30, 2017 (unaudited) and December 31, 2016	0	0
Additional paid-in capital	59,757	48,413
Accumulated deficit	(55,810)	(54,960)
Total stockholders’ equity (deficiency)	3,953	(6,541)
Total liabilities and stockholders’ equity (deficiency)	$ 6,735	$ 3,872

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	9,599,234	5,713,383
Common stock, shares, outstanding	9,599,234	5,713,383
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Temporary Equity, Shares Issued	0	0
Temporary Equity, Shares Outstanding	0	0

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues	$ 1,210	$ 669	$ 2,217	$ 1,237
Cost of revenues	850	826	1,751	1,496
Gross profit (loss)	360	(157)	466	(259)
Operating expenses:
Research and development	1,184	521	1,653	918
Sales and marketing	2,205	1,142	4,030	1,661
General and administrative	1,089	803	3,106	1,708
Total operating expenses	4,478	2,466	8,789	4,287
Operating loss	(4,118)	(2,623)	(8,323)	(4,546)
Financial income (expenses), net:
Revaluation of warrants	25	(1,428)	7,485	(1,850)
Other financial (expense) income, net	1	(6)	(12)	(19)
Total financial income (expenses), net	26	(1,434)	7,473	(1,869)
Net loss	(4,092)	(4,057)	(850)	(6,415)
Deemed dividend related to Series A Preferred Stock exchange agreement	0	0	0	455
Net loss attributable to holders of Common Stock	$ (4,092)	$ (4,057)	$ (850)	$ (6,870)
Net loss per share
Basic and diluted loss per share (in dollars per share)	$ (0.43)	$ (0.73)	$ (0.10)	$ (1.48)
Weighted average number of Common Stock used in computing basic and diluted net loss per share (in shares)	9,521,730	5,587,800	8,377,667	4,644,495

STATEMENTS OF CHANGES IN STOCKH

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($) $ in Thousands	Total		Common Stock [Member]		Additional Paid-in Capital [Member]		Accumulated deficit [Member]
Balance at Dec. 31, 2015	$ (1,580)		$ 5		$ 41,769		$ (43,354)
Balance (in shares) at Dec. 31, 2015			2,911,788
Issuance of Common Stock in March 2016 Public Offering, net of issuance cost	1,572		$ 1		1,571		0
Issuance of Common Stock in March 2016 Public Offering, net of issuance cost (in shares)			1,333,333
Issuance of Common Stock in March 2016 Private Placement, net of issuance cost	828		$ 0	[1]	828		0
Issuance of Common Stock in March 2016 Private Placement, net of issuance cost (in shares)			599,999
Issuance of Common Stock in January 2016 to service provider	37		$ 0	[1]	37		0
Issuance of Common Stock in January 2016 to service provider (in shares)			5,556
Payment for executives, employee and directors under Salary Program	310		$ 0	[1]	310		0
Payment for executives, employee and directors under Salary Program (in shares)			57,910
Issuance of Common Stock in March 2016 to officer	86		$ 0	[1]	86		0
Issuance of Common Stock in March 2016 to officer (in shares)			20,000
Exercise of warrants into Common Stock, net of issuance cost	210		$ 0	[1]	210		0
Exercise of warrants into Common Stock, net of issuance cost (in shares)			77,019
Exercise of non-plan options	0	[1]	$ 0	[1]	0	[1]	0
Exercise of non-plan options (in shares)			84,106
Deemed dividend related to Series A Preferred Stock exchange agreement into Common Stock in March 2016	0		$ 0		455		(455)
Deemed dividend related to Series A Preferred Stock exchange agreement into Common Stock in March 2016 (in shares)			124,737
Deemed dividend related to extension of July 2015 Series A warrants in July 2016	0		$ 0		265		(265)
Conversion of Series A Preferred Stock into Common Stock	2,277		$ 0	[1]	2,277		0
Conversion of Series A Preferred Stock into Common Stock (in shares)			498,935
Stock-based compensation	605		$ 0		605		0
Net loss	(10,887)		0		0		(10,887)
Balance at Dec. 31, 2016	(6,541)		$ 6		48,413		(54,960)
Balance (in shares) at Dec. 31, 2016			5,713,383
Issuance of Common Stock in January 2017 Private Placement, net of issuance cost	2,886		$ 0	[1]	2,886		0
Issuance of Common Stock in January 2017 Private Placement, net of issuance cost (in shares)			1,113,922
Payment for executives, employee and directors under Salary Program	381		$ 0	[1]	381		0
Payment for executives, employee and directors under Salary Program (in shares)			113,747
Issuance of Common Stock in to Employees	1,444		$ 0	[1]	1,444		0
Issuance of Common Stock in to Employees (in shares)			442,257
Issuance of Common Stock to consultants and service provider	180		$ 0	[1]	180		0
Issuance of Common Stock to consultants and service provider (in shares)			58,410
Conversion of Series A Preferred Stock into Common Stock	0
Issuance of Common Stock in March 2017 Private Placement, net of issuance cost	1,878		$ 0	[1]	1,878		0
Issuance of Common Stock in March 2017 Private Placement, net of issuance cost (in shares)			707,515
Issuance of Common Stock in April 2017 Public offering, net of issuance cost	3,855		$ 0	[1]	3,855		0
Issuance of Common Stock in April 2017 Public offering, net of issuance cost (in shares)			1,450,000
Stock-based compensation	720		$ 0		720		0
Net loss	(850)		0		0		(850)
Balance at Jun. 30, 2017	$ 3,953		$ 6		$ 59,757		$ (55,810)
Balance (in shares) at Jun. 30, 2017			9,599,234
[1]	Represents an amount lower than $1.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (850)	$ (6,415)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation and Common Stock to service providers	2,441	668
Depreciation	101	191
Increase in trade receivables	(146)	0
Decrease (increase) in accounts receivables and prepaid expenses	(146)	84
Decrease (increase) in inventories	171	(410)
Decrease (increase) in trade payables	(827)	27
Decrease in deferred revenues	0	(31)
Increase in other accounts payable and accrued expenses	915	238
Change in fair value of warrants to purchase shares of Common Stock	(7,485)	1,850
Net cash used in operating activities	(5,826)	(3,798)
Cash flows from investing activities:
Maturity of (investment in) lease deposits	(7)	1
Purchase of property and equipment	(31)	(246)
Net cash used in investing activities	(38)	(245)
Cash flows from financing activities:
Proceeds from issuance of Common Stock and warrants, net of issuance cost	8,669	7,538
Proceeds from exercise of options and warrants	0	210
Net cash provided by financing activities	8,669	7,748
Increase in cash and cash equivalents	2,805	3,705
Cash and cash equivalents at the beginning of the period	1,093	2,671
Cash and cash equivalents at the end of the period	3,898	6,376
Non-cash investing and financing activities:
Conversion of Series A Preferred Stock to Common Stock	0	2,277
Payment for directors and employees under Stock for Cash Program	$ 183	$ 102

GENERAL

GENERAL	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1: - GENERAL a. DarioHealth Corp. (formerly LabStyle Innovations Corp.) (the “Company”) was incorporated in Delaware and commenced operations on August 11, 2011. The Company is a digital health (mHealth) company that is developing and commercializing a patented and proprietary technology providing consumers with laboratory-testing capabilities using smart phones and other mobile devices. The Company’s flagship product, Dario TM TM TM b. The Company’s wholly owned subsidiary, LabStyle Innovation Ltd. (“Ltd.” or “Subsidiary”), was incorporated and commenced operations on September 14, 2011 in Israel. Its principal business activity is to hold the Company’s intellectual property and to perform research and development, manufacturing, marketing and other business activities. Ltd. has a wholly-owned subsidiary, LabStyle Innovations US LLC, a Delaware limited liability company (“LabStyle US”), which was established in 2014, however it has not started its operations to date. c. During the six months ended June 30, 2017, the Company incurred operating losses and negative cash flows from operating activities amounting to $8,323 and $5,826, respectively. The Company will be required to obtain additional liquidity resources in order to support the commercialization of its products and maintain its research and development activities. The Company is addressing its liquidity needs by seeking additional funding from public and/or private sources and by ramping up its commercial sales. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the short and long-term development and commercialization of its product. According to management estimates, the Company has sufficient liquidity resources to continue its planned activity into January 2018 These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. d. On March 4, 2016, the Company's Common Stock and warrants were approved for listing on NASDAQ Capital Market under the symbols “DRIO” and “DRIOW,” respectively.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 are applied consistently in these unaudited interim consolidated financial statements.

UNAUDITED INTERIM FINANCIAL STA

UNAUDITED INTERIM FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting [Text Block]	NOTE 3: - UNAUDITED INTERIM FINANCIAL STATEMENTS The accompanying unaudited interim consolidated financial statements as of June 30, 2017, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company's consolidated financial position as of June 30, 2017, and the Company's consolidated results of operations and the Company's consolidated cash flows for the six months ended June 30, 2017. Results for the six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 4: - INVENTORIES June 30, December 31, 2017 2016 Unaudited Raw materials $ 330 $ 431 Finished products 387 457 $ 717 $ 888 During the six months’ period ended June 30, 2017 and the year ended December 31, 2016, total inventory write-off expenses amounted to $ 47 315

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 5: - COMMITMENTS AND CONTINGENT LIABILITIES From time to time the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.

STOCKHOLDERS' EQUITY (DEFICIENC

STOCKHOLDERS' EQUITY (DEFICIENCY)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	STOCKHOLDERS' EQUITY (DEFICIENCY) a. On January 9, 2017, the Company commenced a private placement offering of up to $ 5,100 1,821,437 0.0001 1,821,437 5 1,113,922 1,113,922 3,119 2,886 707,515 707,515 1,981 1,878 b. In January and April 2017, 77,891 125,856 c. In January 10, 2017, 6,553 34,050 0.0001 d. In January and February 2017, the Company's Compensation Committee of the Board of Directors approved the grants of 367,257 211,492 286,229 21,000 3.202 4.121 e. On April 5, 2017, the Company closed a public offering (the " " 1,450,000 3.10 3,855 net of issuance costs. The shares were offered, issued and sold pursuant to a shelf registration statement filed with the Securities and Exchange Commission. In connection with the Public Offering, the Company agreed to issue to the representative of the underwriters' five-year warrants to purchase up 36,250 Common Stock at an exercise price equal 3.875 Common Stock for cash or on a cashless basis if no registration statement covering the resale of the shares issuable upon exercise of the warrants is available. f. In April and June 2017, the Company's Compensation Committee of the Board of Directors approved the grants of 56,244 59,000 194,192 to purchase shares of Common Stock 0.0001 2.44 three six g. In April and June 2017, 36,857 of Common Stock were issued 17,500 to purchase shares of Common Stock were granted 0.0001 h. Stock option compensation: Weighted average Weighted Aggregate Number of exercise average Intrinsic options price remaining contractual life value $ Years $ Options outstanding at beginning of year 583,334 16.53 4.87 7 Options granted 813,413 2.02 Options exercised - - Options expired (38,528) 5.37 Options forfeited (20,273) 50.75 Options outstanding at period end (unaudited) 1,337,946 7.63 5.21 540 Options vested and expected to vest at period end (unaudited) 1,217,778 7.88 5.20 540 Exercisable at period end (unaudited) 634,932 12.54 4.88 377 The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on the last day of the second quarter of 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on June 30, 2017. This amount is impacted by the changes in the fair market value of the Common Stock. As of June 30, 2017, the total amount of unrecognized stock-based compensation expense was approximately $ 1,200 1.24 Six months ended 2017 2016 Unaudited Cost of revenues $ 77 $ 19 Research and development 143 53 Sales and marketing 411 62 General and administrative 1,810 534 Total stock-based compensation expenses $ 2,441 $ 668

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	FAIR VALUE MEASUREMENTS Accounting Standards Codification 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. ASC 820 establishes three levels of inputs that may be used to measure fair value: Level 1 - quoted prices in active markets for identical assets or liabilities; Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. On September 23, 2014, the Company consummated a private placement (the “September 2014 Private Placement”) consisting of an aggregate of 42,350 units which consisted of 42,350 10,683,662 5,341,834 0.48 The warrants issued in the September 2014 Private Placement contain a net settlement cash feature and liquidated damages penalties and therefore the Company accounts for such warrants as a liability according to the provisions of ASC 815-40 “Contracts in entity’s own equity,” and re-measures such liability using the Binomial option-pricing model as described below. June 30, Risk-free interest rate (1) 1.28 % Expected volatility (2) 71.43 % Expected life (in years) (3) 1.23 % Expected dividend yield (4) 0 % Fair value per warrant $ 0.06 (1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. (2) Expected volatility - was calculated based on actual historical stock price movements of the Company together with companies in the same industry over a term that is equivalent to the expected term of the option. (3) Expected life - the expected life was based on the expiration date of the warrants. (4) Expected dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. (5) The changes in Level 3 liabilities associated with the warrants are measured at fair value on a recurring basis. The following tabular presentation reflects the components of the liability associated with such warrants as of June 30, 2017: Fair value of liability related to warrants Balance at December 31, 2016 $ 7,488 Change in fair value of warrants during the period (7,485) Balance at June 30, 2017 (unaudited) $ 3

FINANCIAL INCOME (EXPENSES), NE

FINANCIAL INCOME (EXPENSES), NET	6 Months Ended
	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	NOTE 8: - FINANCIAL INCOME (EXPENSES), NET Six months ended 2017 2016 Unaudited Bank charges $ (7) $ (12) Foreign currency translation adjustments (5) (7) Change in fair value of warrants 7,485 (1,850) Total financial income (expenses), net $ 7,473 $ (1,869)

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 9: - SUBSEQUENT EVENTS In July 2017, 71,908 were issued to certain members of the Board of Directors, Officers and employees of the Company as consideration for a reduction in or waiver of cash salary fees and bonuses owed to such individuals. The shares were issued under the Company’s 2012 Plan.

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, 2017 2016 Unaudited Raw materials $ 330 $ 431 Finished products 387 457 $ 717 $ 888

STOCKHOLDERS' EQUITY (DEFICIE17

STOCKHOLDERS' EQUITY (DEFICIENCY) (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Transactions related to the grant of options to employees, directors and non-employees under the above plans during the six-month period ended June 30, 2017 were as follows: Weighted average Weighted Aggregate Number of exercise average Intrinsic options price remaining contractual life value $ Years $ Options outstanding at beginning of year 583,334 16.53 4.87 7 Options granted 813,413 2.02 Options exercised - - Options expired (38,528) 5.37 Options forfeited (20,273) 50.75 Options outstanding at period end (unaudited) 1,337,946 7.63 5.21 540 Options vested and expected to vest at period end (unaudited) 1,217,778 7.88 5.20 540 Exercisable at period end (unaudited) 634,932 12.54 4.88 377
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The total compensation cost related to all of the Company's equity-based awards recognized during the six-month period ended June 30, 2017 and 2016 was comprised as follows: Six months ended 2017 2016 Unaudited Cost of revenues $ 77 $ 19 Research and development 143 53 Sales and marketing 411 62 General and administrative 1,810 534 Total stock-based compensation expenses $ 2,441 $ 668

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Warrants Fair Value [Table Text Block]	June 30, Risk-free interest rate (1) 1.28 % Expected volatility (2) 71.43 % Expected life (in years) (3) 1.23 % Expected dividend yield (4) 0 % Fair value per warrant $ 0.06 (1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds. (2) Expected volatility - was calculated based on actual historical stock price movements of the Company together with companies in the same industry over a term that is equivalent to the expected term of the option. (3) Expected life - the expected life was based on the expiration date of the warrants. (4) Expected dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future. (5) The changes in Level 3 liabilities associated with the warrants are measured at fair value on a recurring basis. The following tabular presentation reflects the components of the liability associated with such warrants as of June 30, 2017:
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tabular presentation reflects the components of the liability associated with such warrants as of June 30, 2017: Fair value of liability related to warrants Balance at December 31, 2016 $ 7,488 Change in fair value of warrants during the period (7,485) Balance at June 30, 2017 (unaudited) $ 3

FINANCIAL INCOME (EXPENSES), 19

FINANCIAL INCOME (EXPENSES), NET (Tables)	6 Months Ended
	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Six months ended 2017 2016 Unaudited Bank charges $ (7) $ (12) Foreign currency translation adjustments (5) (7) Change in fair value of warrants 7,485 (1,850) Total financial income (expenses), net $ 7,473 $ (1,869)

GENERAL (Details Textual)

GENERAL (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Organization And Presentation Of Financial Statements [Line Items]
Operating Income (Loss)	$ (4,118)	$ (2,623)	$ (8,323)	$ (4,546)
Net Cash Provided by (Used in) Operating Activities			$ (5,826)	$ (3,798)

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory [Line Items]
Raw materials	$ 330	$ 431
Finished products	387	457
Inventory, Net	$ 717	$ 888

INVENTORIES (Details Textual)

INVENTORIES (Details Textual) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory Write-down	$ 47	$ 315

STOCKHOLDERS' EQUITY (DEFICIE23

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details) - Employee Stock Option [Member] $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding at beginning of year, Number of options | shares	583,334
Options granted, Number of options | shares	813,413
Options exercised, Number of options | shares	0
Options expired, Number of options | shares	(38,528)
Options forfeited, Number of options | shares	(20,273)
Options outstanding at end of year, Number of options | shares	1,337,946	583,334
Options vested and expected to vest at end of year, Number of options | shares	1,217,778
Exercisable at end of year, Number of options | shares	634,932
Options outstanding at beginning of year, Weighted average exercise price | $ / shares	$ 16.53
Options granted, Weighted average exercise price | $ / shares	2.02
Options exercised, Weighted average exercise price | $ / shares	0
Options expired, Weighted average exercise price | $ / shares	5.37
Options forfeited, Weighted average exercise price | $ / shares	50.75
Options outstanding at end of year, Weighted average exercise price | $ / shares	7.63	$ 16.53
Options vested and expected to vest at end of year, Weighted average exercise price | $ / shares	7.88
Exercisable at end of year, Weighted average exercise price | $ / shares	$ 12.54
Options outstanding at, Weighted average remaining contractual life	5 years 2 months 16 days	4 years 10 months 13 days
Options vested and expected to vest at end of year, Weighted average remaining contractual life	5 years 2 months 12 days
Exercisable at end of year, Weighted average remaining contractual life	4 years 10 months 17 days
Options outstanding, Aggregate Intrinsic value | $	$ 540	$ 7
Options vested and expected to vest at end of year, Aggregate Intrinsic value | $	540
Exercisable at end of year, Aggregate Intrinsic value | $	$ 377

STOCKHOLDERS' EQUITY (DEFICIE24

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details 1) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	$ 2,441	$ 668
Cost of revenues [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	77	19
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	143	53
Sales, Marketing and pre-production costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	411	62
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expenses	$ 1,810	$ 534

STOCKHOLDERS' EQUITY (DEFICIE25

STOCKHOLDERS' EQUITY (DEFICIENCY) (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

Feb. 06, 2017

Jan. 11, 2017

Jan. 10, 2017

Apr. 30, 2017

Apr. 05, 2017

Mar. 09, 2017

Feb. 28, 2017

Jan. 31, 2017

Jan. 09, 2017

Jun. 30, 2017

Jun. 30, 2017

Dec. 31, 2016

Class of Stock [Line Items]

Issuance of Common Stock in April 2017 Public offering, net of issuance cost

$ 3,855

$ 1,572

Stock Issued During Period, Shares, New Issues

1,450,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options

$ 1,200

$ 1,200

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

1 year 2 months 26 days

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

36,250

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 3.875

Stock Issued During Period Shares New Issues February 2014

1,821,437

Proceeds from Issuance of Private Placement

$ 5,100

Shares Issued, Price Per Share

$ 3.10

Common Stock, Par Or Stated Value Per Share

$ 0.0001

$ 0.0001

$ 0.0001

Equity Incentive Plan 2012 [Member]

Class of Stock [Line Items]

Issuance of Common Stock in April 2017 Public offering, net of issuance cost

$ 6,553

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

34,050

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.0001

Officer [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

211,492

Board of Director and Officers [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross

125,856

77,891

Employees [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

286,229

Employees [Member] | Equity Incentive Plan 2012 [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

59,000

Consultants [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

21,000

Consultants [Member] | Equity Incentive Plan 2012 [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

194,192

Employees Directors And Consultants [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

6 years

Stock Issued During Period, Shares, Share-based Compensation, Gross

367,257

Employees Directors And Consultants [Member] | Minimum [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 3.202

Employees Directors And Consultants [Member] | Maximum [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 4.121

Employees And Consultants [Member] | Equity Incentive Plan 2012 [Member] | Minimum [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.0001

Employees And Consultants [Member] | Equity Incentive Plan 2012 [Member] | Maximum [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 2.44

Service Provider [Member] | Equity Incentive Plan 2012 [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, Share-based Compensation, Gross

56,244

Service Provider [Member] | Amended and Restated 2012 Equity Incentive Plan [Member]

Class of Stock [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

17,500

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.0001

Stock Issued During Period, Shares, Share-based Compensation, Gross

36,857

Private Placement [Member]

Class of Stock [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,821,437

Proceeds from Issuance of Private Placement

$ 3,119

Exercisable Term

5 years

Payments of Stock Issuance Costs

$ 2,886

Common Stock, Par Or Stated Value Per Share

$ 0.0001

Private Placement [Member] | Investor [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

1,113,922

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

1,113,922

Securities Purchase Agreements [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

707,515

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

707,515

Proceeds from Issuance of Private Placement

$ 1,981

Payments of Stock Issuance Costs

$ 1,878

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Investors Warrants [Member] - September 2014 Private Placement [Member]	6 Months Ended
	Jun. 30, 2017$ / shares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.28%	[1]
Expected volatility	71.43%	[2]
Expected life (in years)	1 year 2 months 23 days	[3]
Expected dividend yield	0.00%	[4]
Fair value per warrant	$ 0.06
[1]	Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.
[2]	Expected volatility - was calculated based on actual historical stock price movements of the Company together with companies in the same industry over a term that is equivalent to the expected term of the option.
[3]	Expected life - the expected life was based on the expiration date of the warrants.
[4]	Expected dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future.

FAIR VALUE MEASUREMENTS (Deta27

FAIR VALUE MEASUREMENTS (Details 1) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Balance at December 31, 2016	$ 7,488
Change in fair value of warrants during the period	(7,485)
Balance at June 30, 2017	$ 3

FAIR VALUE MEASUREMENTS (Deta28

FAIR VALUE MEASUREMENTS (Details Textual) - $ / shares	1 Months Ended
	Sep. 23, 2014	Apr. 05, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		36,250
September 2014 Private Placement [Member]
Warrants Exercise Price Per Share Adjusted	$ 0.48
Preferred Units, Issued	42,350
Preferred Stock Convertible Into Common Stock	10,683,662
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,341,834

FINANCIAL INCOME (EXPENSES), 29

FINANCIAL INCOME (EXPENSES), NET (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Selected Statements Of Operations Data [Line Items]
Bank charges			$ (7)	$ (12)
Foreign currency translation adjustments			(5)	(7)
Change in fair value of warrants	$ 25	$ (1,428)	7,485	(1,850)
Total financial income (expenses), net	$ 26	$ (1,434)	$ 7,473	$ (1,869)

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual)	1 Months Ended
	Jul. 28, 2017shares
Subsequent Event [Member] | Board of Director and Officer [Member] | Amended and Restated 2012 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	71,908